

1 **Effect of nasal carriage of *Bacillus* species on COVID-19 severity:**

2 **A cross-sectional study**

3 Muinah A. Fowora,^{a#} Adenike Aiyedogbon,^a Ibilola Omolopo,^a Ahmed O. Tajudeen,^a Abdul-
4 Lateef Olanlege,^b Adefunke Abioye,^b Grace B. Akintunde,^a Morenike O. Folayan,^c Babatunde L.
5 Salako^a

6 ^aMolecular Biology and Biotechnology Department, Nigerian Institute of Medical Research,
7 Yaba, Lagos, Nigeria

8 ^bInfectious Diseases Hospital, Lagos, Nigeria

9 ^cDepartment of Child Dental Health, College of Health Sciences, Obafemi Awolowo University

10
11 Running Head: *Bacillus* species in the nasopharynx and COVID-19
12

13
14 #Address correspondence to Muinah A. Fowora, muinahj@yahoo.com
15
16

17 **ABSTRACT**

18 Intranasal sprays containing *Bacillus* species are being researched for treating viral respiratory
19 tract infections. The aim of this study was to assess the relationship between the nasal carriage of
20 *Bacillus* and COVID-19 severity. This was a cross-sectional study that collected nasopharyngeal
21 samples from adults 18 years and above visiting two COVID-19 testing centers in Lagos, Nigeria
22 between September 2020 and September 2021. *Bacillus* species were cultured from the
23 respiratory samples and confirmed using molecular methods. The dependent variable was

24 COVID-19 status classified as negative, asymptomatic, mild, or severe. The independent
25 variable was the nasal carriage of *Bacillus* species. Multinomial regression analysis was done to
26 determine the association between nasal carriage of *Bacillus* and COVID-19 severity after
27 adjusting for age, sex, and co-morbidity status. About 388 participants were included in the study
28 with a mean (standard deviation) age of 40.05 (13.563) years. The majority (61.1%) of the
29 participants were male, 100 (25.8%) had severe COVID-19, 130 (33.5%) had pre-existing
30 comorbidity, and 76 (19.6%) had *Bacillus* cultured from their nasopharyngeal specimen. *Bacillus*
31 species presence was significantly associated with higher odds of severe COVID-19 compared to
32 having a negative COVID-19 status. However, the presence of *Bacillus* species was significantly
33 associated with lower odds of severe COVID-19 compared to having a mild COVID-19 status.
34 The study suggests that nasal carriage of *Bacillus* species may substantially impact the clinical
35 course of COVID-19. This study supports the exploration of *Bacillus* species in the prevention
36 and management of viral respiratory tract infections.

37 **IMPORTANCE**

38 With the introduction of intranasal spray containing *Bacillus* species for the treatment of viral
39 respiratory tract infections, such as COVID-19 and respiratory syncytial virus, identifying the
40 association between the nasal carriage of *Bacillus* species and COVID-19 susceptibility and
41 severity will help further substantiate the investigation of these bacteria for COVID-19
42 prevention and treatment. This study evaluated the association between the carriage of *Bacillus*
43 species in the nasopharyngeal tract and COVID-19 severity and found that the presence of
44 *Bacillus* species in the nasopharynx may significantly impact the clinical course of COVID-19.

45

46

47 BACKGROUND

48 Corona Virus Disease 2019 (COVID-19), an acute and highly infectious respiratory disease
49 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the
50 death of more than 6.42 million people globally since its outbreak in Wuhan, China in 2019 [1].
51 Several factors such as the nasal microbiota determine the susceptibility and severity of the
52 disease [2-7]. Microbiota can confer some level of protection on the host against some diseases
53 by creating a unique microbial ecosystem that enhances resistance against the manifestation of
54 respiratory tract infection caused by bacterial, fungal, and/or viral pathogens [8, 9]. It also serves
55 as markers of disease [10] and the regulation of local and systemic immunity in the
56 nasopharyngeal tract thereby influencing COVID-19 susceptibility and clinical outcome [7]. In
57 addition, viral infection modifies the host's nasal microbiota, decreases the nasal and gut
58 microbiota diversity, and increases the disease infectivity and severity [11, 12].

59 A significant increase in bacteria belonging to the phyla Bacteroides, Proteobacteria,
60 Actinobacteria, Firmicutes, and Fusobacteria have been reported among COVID-19 patients [13]
61 though some other study did not find a significant difference in the nasal bacterial composition
62 and diversity in patients with COVID-19 when compared with patients negative for COVID-19
63 [14]. The members of bacteria belonging to the phylum Firmicutes, especially of the class
64 Bacilli, have been associated with respiratory immunity and strengthening the host defense
65 against respiratory viral infections [11]. *Bacillus* has been explored as intranasal sprays for the
66 treatment of viral infection [15, 16] as it eases the symptoms of acute respiratory tract infection
67 caused by respiratory syncytial virus by reducing the viral load and inflammation associated with
68 the disease [16]. *Bacillus subtilis* possesses the probiotic potential to increase mucosal and
69 tonsillar immunity against respiratory diseases through the formation of immune cells in the

70 nasal cavity and tonsil [15]. Like bacilli intranasal sprays, lactobacilli-containing throat sprays
71 have also been demonstrated to considerably lessen the acute symptoms of COVID-19 as well as
72 the load of the virus in the nasopharynx [17]. However, there are currently no studies showing
73 the effect of nasal carriage of *Bacillus* species on the susceptibility to SARS-CoV-2 infection and
74 severity.

75 The aim of this study was to determine the association between nasal carriage of *Bacillus species*
76 and COVID-19 susceptibility and severity. We hypothesize that there will be a negative
77 association between nasal carriage of *Bacillus* and COVID-19 susceptibility and severity.

78 **METHODS**

79 **Study design and population**

80 This study was a cross-sectional study that compared the prevalence of nasal carriage of *Bacillus*
81 species among adult who were tested positive or negative for COVID-19 in Lagos State, Nigeria.
82 The study population included individuals ≥ 18 years, who present for SARS-CoV-2 testing at
83 the COVID-19 modified drive-through centre of the Nigerian Institute of Medical Research and
84 the laboratory of the Infectious Disease Hospital, Lagos. The participants were recruited between
85 September 2020 to September 2021. Adults who had travelled out of the country in the last one
86 month of the survey were excluded from the study. Informed consents were appropriately
87 obtained from all eligible participants.

88 **Sample size and sampling technique**

89 The sample size for this study was determined using the formula for sample size calculations for
90 prevalence studies [18]. The standard normal variate was set at 5% type I error; the precision
91 was set at 0.05; and the expected proportion of adults with nasal *Bacillus* was set at 50% in the

92 absence of any available data. The minimum sample size was 385. The sample size was
93 increased to 450 participants to account for missing data or invalid COVID-19 results. A
94 convenient sample of participants willing to participate in the study was recruited.

95 **Data collection**

96 Information on the age (age as at last birthday) and sex (sex at birth) of participants were
97 collected. Other information collected were the symptoms and severity of the patient and if the
98 participant had any underlying conditions such as diabetes, asthma, hypertension, heart, lung,
99 and kidney disease. These variables had been identified factors that influence COVID-19
100 susceptibility and severity [19, 20]. No identifying information was collected from the
101 participants.

102 Participants were classified as positive for COVID-19 when the results on the real-time reverse
103 transcription–polymerase-chain-reaction (RT-PCR) assay of their nasopharyngeal swab
104 specimens was positive. Participants with positive test results were categorized as asymptomatic,
105 mild or severe cases using the guidelines of the Nigeria Centre for Disease Control and the
106 National Institute of Health [21, 22]. Asymptomatic cases were defined as patients that had no
107 symptoms specific to COVID-19 but tested positive SARS-CoV-2. Mild cases were patients who
108 had symptoms corresponding to COVID-19 such as fever ($<38^{\circ}\text{C}$), cough, sore throat, malaise,
109 headache, muscle pain, loss of taste and smell, nausea, vomiting, diarrhea, abdominal pain, but
110 do not have difficulty breathing, dyspnea and any underlying conditions. Severe cases were
111 patients with clinical manifestations of COVID-19 in conjunction with difficulty in breathing,
112 reduced/decreased breath sounds, dullness in percussion, increased or decreased vocal resonance,
113 and presence of an underlying comorbid condition such as diabetes, asthma, hypertension, heart,
114 lung, asthma and kidney disease.

115

116 **Sample collection and analysis**

117 Nasopharyngeal swab samples were collected from the participants into two different transport
118 media. One containing a viral transport medium (VTM) and the other a bacterial transport
119 medium containing Tryptone soy broth buffered with 2.5% saline and 10% glycerol. All samples
120 were analyzed within one to two hours of specimen collection.

121 ***RNA extraction and qRT-PCR***

122 Viral Nucleic acid Extraction was carried out on the nasopharyngeal sample in VTM using the
123 Qiagen Viral Extraction kit according to manufacturer's instructions, and SARS-CoV-2 was
124 detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR) using a
125 commercial Nucleic Acid Diagnostic Kit for COVID-19, Sansure Novel Coronavirus (2019-
126 nCoV), according to manufacturer's protocol (Sansure Biotech Inc). The Sansure kit has high
127 sensitivity and is endorsed for the SARS-CoV-2 testing [23].

128 ***Bacteria isolation***

129 The nasopharyngeal samples in the bacteria transport medium were plated on Mueller Hinton
130 Agar and de Man-Rogosa Sharpe (MRS) agar (Oxoid, USA) using a disposable loop. The
131 nutrient agar was incubated aerobically at 37⁰C for 24 hours while the MRS agar was incubated
132 at 37⁰C under anaerobic conditions using a anaerobic jar containing an anaerobic gas generating
133 pack (Thermo Scientific™ Oxoid™ AnaeroGen™) for 48 to 72 hours.

134 ***Bacterial identification***

135 Isolates were identified based on the morphological characteristics of the colony and using both
136 phenotypic and molecular methods. The phenotypic based methods included Gram staining,
137 nitrate reduction, gelatin hydrolysis, and citrate utilization as previously described [24, 25].

138 Deoxyribonucleic acid (DNA) was extracted from all the presumptively identified bacteria using
139 the NIMR Biotech DNA extraction kit. To confirm the identification of the *Bacillus* species,
140 polymerase chain reaction amplification of the 16s rRNA gene specific for *Bacillus* was carried
141 out. The reaction was done using the primer set 16S-HV (Forward primer -5'-
142 TGTA AACGACGGCCAGTGCCTAATACATGCAAGTCGAGCG-3' and Reverse primer-
143 5'- CAGGAAACAGCTATGACCACTGCTGCCTCCCGTAGGAGT-3') as previously
144 described [26].

145 Polymerase chain reaction was done using the Solis Biodyne 5X HOT FIREPol Blend Master
146 mix in a 20 µl reaction mixture, containing 1X Blend Master mix buffer (Solis Biodyne), 1.5
147 mM MgCl₂, 200µM of each deoxynucleoside triphosphates (dNTP)(Solis Biodyne), 25pMol of
148 each primer (BIOMERS, Germany), 2 unit of Hot FIREPol DNA polymerase (Solis Biodyne),
149 Proofreading Enzyme, 5µl of the extracted DNA, and sterile nuclease- free water was used to
150 make up the reaction mixture.

151 Thermal cycling was conducted in a PTC 200 gradient thermal Cyler Eppendorf for an initial
152 denaturation of 95°C for 15 minutes followed by 35 amplification cycles of 30 seconds at 95°C,
153 one minute at 58°C and one minute 30 Seconds at 72°C. This was followed by a final extension
154 step of 10 minutes at 72°C. The amplification product was separated on a 1.5% agarose gel and
155 electrophoresis was carried out at 80V for 1 hour 30 minutes. After electrophoresis, DNA bands
156 were visualized by ethidium bromide staining. 100bp DNA ladder was used as DNA molecular
157 weight standard.

158 **STATISTICAL ANALYSIS**

159 The study variables were presented as means (standard deviations) or frequencies and
160 percentages. A multivariate logistic regression model was developed to determine the association
161 between COVID-19 status (negative, asymptomatic, mild and severe) and *Bacillus* species
162 isolation status dichotomized into positive and negative. The model was adjusted for age, sex,
163 and presence of comorbidity. Statistical analysis was done using SPSS version 26.0 and
164 statistical significance was set at a p value ≤ 0.05 .

165 **ETHICAL CONSIDERATIONS**

166 Ethical approval was obtained from the Institutional Review Board of the Nigerian Institute of
167 Medical Research (IRB/20/043). A written informed consent was obtained from all the
168 participants following the national ethics guidelines [27].

169 **RESULTS**

170 There were 450 study participants recruited into this study. Forty-three (9.6%) had invalid
171 COVID-19 qRT-PCR and the information on the age and/or sex was missing for 19 (4.2%)
172 participants. The complete data for 388 participants is presented in Table 1.

173 The age of participants ranged from 18 to 75 years with the mean age (standard deviation) age of
174 40.05 (13.563) years. Also, 237 (61.1%) participants were male, 228 (58.8%) had a negative
175 COVID-19 test result and 258 (66.5%) had no pre-existing medical condition. Among
176 participants that reported having a pre-existing condition, 71 (18.3%) had high blood pressure
177 and 22 (5.7%) had both type II diabetes mellitus and high blood pressure. There were *Bacillus*
178 species isolated from 76 (19.6%) of the nasopharyngeal samples collected.

179 Table 1. Age, sex, COVID-19 severity, pre-existing conditions, and *Bacillus* isolation from the
 180 nasopharyngeal samples of adult Nigerians with COVID-19 (N = 388)

Factor	Variable	Statistic
Sex	Female: n (%)	151 (38.9)
	Male: n (%)	237 (61.1)
Age	Mean (SD)	40.05 (13.563)
COVID-19	Negative n (%)	228 (58.8)
	Asymptomatic n (%)	28 (7.2)
	Mild n (%)	32 (8.2)
	Severe n (%)	100 (25.8)
Pre-existing Condition	Yes n (%)	130 (33.5)
	No n (%)	258 (66.5)
Type of pre-existing condition	None n (%)	258 (66.5)
	Asthma n (%)	15 (3.9)
	Diabetes n (%)	14 (3.6)
	Hepatitis B n (%)	3 (0.8)
	High blood pressure/Hypertension n (%)	71 (18.3)
	Rhinosinusitis n (%)	1 (0.3)
	Diabetes and High Blood Pressure n (%)	22 (5.7)
	Ulcer n (%)	4 (1.0)
<i>Bacillus</i> isolated	No n (%)	312 (80.4%)
	Yes n (%)	76 (19.6)

182 Table 2 shows that the presence of *Bacillus* species in the nasopharyngeal samples was also
 183 associated with COVID-19 severity: patients with *Bacillus* species in the nasopharyngeal
 184 samples had significantly higher odds for severe COVID-19 than a negative COVID-19 result
 185 (AOR = 3.347, 95% CI: 1.359, 8.243). Also, patients with *Bacillus* species in the nasopharyngeal
 186 samples had significantly lower odds for severe COVID-19 than a mild COVID-19 result (AOR
 187 = 0.158, 95% CI: 0.055, 0.455).

188

189 Table 2. Associations between Age, comorbidity, and the presence of nasal carriage of *Bacillus*
 190 species and COVID-19 Severity (N = 388).

Variable	Severe vs. Negative		Severe vs. Asymptomatic		Severe vs. Mild	
	AOR (95% CI)	P	AOR (95% CI)	p	AOR (95% CI)	P
Age	0.912 (0.884, 0.941)	<0.001*	0.928 (0.884, 0.973)	0.002*	0.891 (0.849, 0.934)	0.183
Sex	0.645 (0.325, 1.282)	0.211	0.951 (0.324, 2.789)	0.927	0.518 (0.197, 1.365)	0.183
Presence of a co-morbidity	0.587 (0.495, 0.696)	<0.001*	-	-	0.7529 (0.561, 0.947)	0.018*
<i>Bacillus</i>	3.347 (1.359, 8.243)	0.009*	0.381 (0.123, 1.182)	0.095	0.158 (0.055, 0.455)	0.001*

AOR: Adjusted odds ratio; B: CI: Confidence interval; *: Statistically significant at P< 0.05. The reference category is severe.

191

192 **Discussion**

193 The objective of this study was to determine if there was an association between the nasal
194 carriage of *Bacillus* species and COVID-19 severity. The study findings showed a strong positive
195 association between nasal carriage of *Bacillus* species and COVID-19 severity while participants
196 who carried *Bacillus* species in their upper respiratory tract had a lower likelihood of developing
197 severe COVID-19 when compared with mild cases. The study findings did not support the study
198 hypothesis of a negative relationship between nasal carriage of *Bacillus* species and COVID-19
199 severity.

200 This is the first study showing a relationship between bacteria co-infection involving nasal
201 carriage of *Bacillus* species and COVID-19. The *Bacillus* species isolated in this study can be
202 classified as a co-infection as they were recovered from the participants at the point of SARS-
203 CoV-2 infection diagnosis [37]. Our study results indicated that attention needs to be given to
204 *Bacillus* species as a secondary bacterial co-infection in COVID-19 and a possible risk factor for
205 severe COVID 19. Prior studies that evaluated respiratory bacteria co-infection in patients with
206 COVID-19 identified *Acinetobacter baumannii*, *Staphylococcus aureus*, *Klebsiella*
207 *pneumoniae* and *Staphylococcus aureus* as the most isolated bacterial infection from respiratory
208 tract cultures [38-40]. We had also reported an association between the nasal carriage
209 of *Moraxella catarrhalis* and *Chlamydomphila pneumoniae* and COVID-19 [41].

210 The observed association between *Bacillus species*, a respiratory opportunistic pathogen, and the
211 severity of COVID-19 may be connected to its association with the high risk for co-morbidities
212 in patients with severe COVID-19. *Bacillus* counts are high in patients who are
213 immunocompromised and patients with diabetes [28, 30-32]. These co-morbidities increase the
214 risk for severe COVID-19. The study finding may influence the development of nasal sprays for

215 the treatment of respiratory viral infections [15, 16]. There is still a need to further identify (up
216 to strain level) the *Bacillus* species isolated and characterize the isolates by antibiotic
217 susceptibility and virulence to better understand the properties of the isolates that may influence
218 the severity of COVID-19.

219 We also found that individuals with *Bacillus* species in their upper respiratory tract may have a
220 lower likelihood of developing severe COVID-19 when compared with mild cases. This finding
221 is similar to the outcome of a prior study that demonstrated that treatment with lactobacilli had
222 the potential to lower the viral load of SARs-COV-2 in the upper respiratory tract without
223 necessarily resolving the symptoms of COVID-19 [17]. The lower likelihood of severe COVID-
224 19 compared to mild COVID-19 when *Bacillus* is present may also be related to the reduction or
225 improvement of the symptoms of SARs-COV-2 infection by the *Bacillus* species. Metabolites,
226 such as surfactins, iturin A, and fengycins produced by some *Bacillus* species have antibacterial
227 and antifungal activities [33-36]. These metabolites may be responsible in easing the symptoms
228 of COVID-19 and preventing the progression of the severity of the disease in mild cases of
229 COVID-19. There is a need to further substantiate this result in a prospective study.

230 This study has its limitations. The cross-sectional study design used limits the generalizability of
231 the results and can only suggest an association and not a cause-effect relationship. The use of
232 nasopharyngeal respiratory tract cultures also limits the interpretation of this findings as upper
233 respiratory tract samples are more subject to contamination and commensal pathogens, and thus
234 bacterial isolation from such specimen are often higher than those from blood cultures [38]. We
235 could not collect specimen from the lower respiratory tract of the participants in this study as
236 most of the participants did not have a productive cough. However, there is a need for further
237 study to determine the pathogenicity of the *Bacillus* species and the role this plays in COVID-19

238 severity. The use of lower respiratory tract specimen and/or blood culture should also be
239 explored to further validate the association between *Bacillus* species co-infection and COVID-19
240 severity.

241 **CONCLUSION**

242 This study suggests that the presence of *Bacillus* species in the nasopharyngeal tract could
243 significantly influence the clinical progression or severity of COVID-19. This study supports the
244 exploration of *Bacillus* species in the prevention and management of COVID-19.

245 **ACKNOWLEDGMENTS**

246 This study was funded with funds from the Nigeria Institute of Medical Research (NMG-CIF-18-
247 0036) and the early career research grant of the Royal Society of Tropical Medicine and
248 Hygiene.

249 We also thank Rukayat Raji and Khadijah Sanusi for their laboratory support, and the Lagos
250 State Ministry of Health.

251

252 **REFERENCES**

- 253 1. Coronavirus disease (COVID-19) pandemic. 7 Mar 2023.
254 <https://www.who.int/europe/emergencies/situations/covid-19>
- 255 2. Jochems SP, Ferreira DM, Smits HH. 2021. Microbiota and compartment matter in the
256 COVID-19 response. *Nat Immunol* 22:1350–1352.
- 257 3. Rueca, M., Fontana, A., Bartolini, B., Piselli, P., Mazzarelli, A., Copetti, M., Binda, E., Perri,
258 F., Gruber, C. E. M., Nicastri, E., Marchioni, L., Ippolito, G., Capobianchi, M. R., Di Caro,

259 A., Paziienza, V. 2021. Investigation of Nasal/Oropharyngeal Microbial Community of
260 COVID-19 Patients by 16S rDNA Sequencing. *Int J Environ Res Public Health* 18(4), 2174.

261 4. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y,
262 Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. 2020. Clinical course and risk factors for
263 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
264 *Lancet* 395(10229), 1054–1062

265 5. Severe Covid-19 GWAS Group; Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A,
266 Invernizzi P, Fernández J, Prati D, Baselli G, Asselta R, Grimsrud MM, Milani C, Aziz F,
267 Kässens J, May S, Wendorff M, Wienbrandt L, Uellendahl-Werth F, Zheng T, Yi X, de
268 Pablo R, Chercoles AG, Palom A, Garcia-Fernandez AE, Rodriguez-Frias F, Zanella A,
269 Bandera A, Protti A, Aghemo A, Lleo A, Biondi A, Caballero-Garralda A, Gori A, Tanck A,
270 Carreras Nolla A, Latiano A, Fracanzani AL, Peschuck A, Julià A, Pesenti A, Voza A,
271 Jiménez D, Mateos B, Nafria Jimenez B, Quereda C, Paccapelo C, Gassner C, Angelini C,
272 Cea C, Solier A, Pestaña D, Muñoz-Diaz E, Sandoval E, Paraboschi EM, Navas E, García
273 Sánchez F, Ceriotti F, Martinelli-Boneschi F, Peyvandí F, Blasi F, Téllez L, Blanco-Grau A,
274 Hemmrich-Stanisak G, Grasselli G, Costantino G, Cardamone G, Foti G, Aneli S, Kurihara
275 H, ElAbd H, My I, Galván-Femenia I, Martín J, Erdmann J, Ferrusquía-Acosta J, Garcia-
276 Etxebarria K, Izquierdo-Sanchez L, Bettini LR, Sumoy L, Terranova L, Moreira L, Santoro
277 L, Scudeller L, Mesonero F, Roade L, Rühlemann MC, Schaefer M, Carrabba M, Riveiro-
278 Barciela M, Figuera Basso ME, Valsecchi MG, Hernandez-Tejero M, Acosta-Herrera M,
279 D'Angiò M, Baldini M, Cazzaniga M, Schulzky M, Cecconi M, Wittig M, Ciccarelli M,
280 Rodríguez-Gandía M, Bocciolone M, Miozzo M, Montano N, Braun N, Sacchi N, Martínez
281 N, Özer O, Palmieri O, Faverio P, Preatoni P, Bonfanti P, Omodei P, Tentorio P, Castro P,

282 Rodrigues PM, Blandino Ortiz A, de Cid R, Ferrer R, Gualtierotti R, Nieto R, Goerg S,
283 Badalamenti S, Marsal S, Matullo G, Pelusi S, Juzenas S, Aliberti S, Monzani V, Moreno V,
284 Wesse T, Lenz TL, Pumarola T, Rimoldi V, Bosari S, Albrecht W, Peter W, Romero-Gómez
285 M, D'Amato M, Duga S, Banales JM, Hov JR, Folseraas T, Valenti L, Franke A, Karlsen TH.
286 2020. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. *N Engl J*
287 *Med* 383(16):1522-1534.

288 6. Göker H, Aladağ Karakulak E, Demiroğlu H, Ayaz Ceylan ÇM, Büyükaşık Y, Inkaya AÇ,
289 Aksu S, Sayinalp N, Haznedaroğlu IC, Uzun Ö, Akova M, Özcebe OI, Ünal S. 2020. The
290 effects of blood group types on the risk of COVID-19 infection and its clinical outcome.
291 *Turk J Med Sci* 50(4):679-683.

292 7. Smith N, Goncalves P, Charbit B, Grzelak L, Beretta M, Planchais C, Bruel T, Rouilly V,
293 Bondet V, Hadjadj J, Yatim N, Pere H, Merklings SH, Ghazlane A, Kernéis S, Rieux-Laucat
294 F, Terrier B, Schwartz O, Mouquet H, Duffy D, Di Santo JP. 2021. Distinct systemic and
295 mucosal immune responses during acute SARS-CoV-2 infection. *Nat Immunol* 22(11):1428-
296 1439

297 8. Brugger SD, Bomar L, Lemon KP. 2016. Commensal-pathogen interactions along the human
298 nasal passages. *PLoS Pathog* 12: e1005633

299 9. Bosch AATM, de Steenhuijsen Piters WAA, van Houten MA, Chu MLJN, Biesbroek G,
300 Kool J, Pernet P, de Groot PCM, Eijkemans MJC, Keijser BJJ, Sanders EAM, Bogaert D.
301 2017. Maturation of the Infant Respiratory Microbiota, Environmental Drivers, and Health
302 Consequences. A Prospective Cohort Study. *Am J Respir Crit Care Med* 196(12):1582-1590.

303 10. Liu J, Liu S, Zhang Z, Lee X, Wu W, Huang Z, Lei Z, Xu W, Chen D, Wu X, Guo Y, Peng
304 L, Lin B, Chong Y, Mou X, Shi M, Lan P, Chen T, Zhao W, Gao Z. 2021. Association

- 305 between the nasopharyngeal microbiome and metabolome in patients with COVID-19. *Synth*
306 *Syst Biotechnol* 6(3):135-143.
- 307 11. Sencio V, Machado MG, Trottein F. 2021. The lung-gut axis during viral respiratory
308 infections: the impact of gut dysbiosis on secondary disease outcomes. *Mucosal Immunol*
309 14(2):296-304.
- 310 12. Dimitri-Pinheiro S, Soares R, Barata P. 2020. The microbiome of the nose-friend or foe?
311 *Allergy Rhinol (Providence)* 11: 2152656720911605. doi:10.1177/2152656720911605
- 312 13. Kolhe R, Sahajpal NS, Vyavahare S, Dhanani AS, Adusumilli S, Ananth S, Mondal AK,
313 Patterson GT, Kumar S, Rojiani AM, Isales CM, Fulzele S. 2021. Alteration in
314 Nasopharyngeal Microbiota Profile in Aged Patients with COVID-19. *Diagnostics (Basel)*
315 11(9):1622.
- 316 14. De Maio F, Posteraro B, Ponziani FR, Cattani P, Gasbarrini A, Sanguinetti M. 2020.
317 Nasopharyngeal Microbiota profiling of SARS-CoV-2 infected patients. *Biol Proced Online*
318 22:18.
- 319 15. Yang Y, Jing Y, Yang J, Yang Q. 2018. Effects of intranasal administration with *Bacillus*
320 *subtilis* on immune cells in the nasal mucosa and tonsils of piglets. *Exp Ther Med* 15: 5189–
321 5198.
- 322 16. Tran DM, Tran TT, Phung TTB, Bui HT, Nguyen PTT, Vu TT, Ngo NTP, Nguyen MT,
323 Nguyen AH, Nguyen ATV. 2022. Nasal-spraying *Bacillus* spores as an effective
324 symptomatic treatment for children with acute respiratory syncytial virus infection. *Sci Rep*
325 12(1):12402.
- 326 17. De Boeck I, Cauwenberghs E, Spacova I, Gehrman T, Eilers T, Delanghe L, Wittouck S,
327 Bron PA, Henkens T, Gamgami I, Simons A, Claes I, Mariën J, Ariën KK, Bakokimi D,

- 328 Loens K, Jacobs K, Ieven M, Bruijning-Verhagen P, Delputte P, Coenen S, Verhoeven V,
329 Lebeer S. 2022. Randomized, Double-Blind, Placebo-Controlled Trial of a Throat Spray with
330 Selected Lactobacilli in COVID-19 Outpatients. *Microbiol Spectr* 10(5):e0168222
- 331 18. Arya R, Antonisamy B, Kumar S. 2012. Sample size estimation in prevalence studies. *Indian*
332 *J Pediatr*. 79: 1482–1488.
- 333 19. Erinoso OA, Wright KO, Anya S, Bowale A, Adejumo O, Adesola S, Osikomaiya B, Mutiu
334 B, Saka B, Falana A, Ola-Ayinde D, Akase EI, Owuna H, Abdur-Razzaq H, Lajide D, Ezechi
335 O, Ogboye O, Osibogun A, Abayomi A. 2020. Clinical characteristics, predictors of
336 symptomatic coronavirus disease 2019 and duration of hospitalisation in a cohort of 632
337 Patients in Lagos State, Nigeria. *Niger Postgrad Med J* 27(4):285-292.
- 338 20. Shoaib N, Noureen N, Munir R, Shah FA, Ishtiaq N, Jamil N, Batool R, Khalid M, Khan I,
339 Iqbal N, Zaidi N. 2021. COVID-19 severity: Studying the clinical and demographic risk
340 factors for adverse outcomes. *PLoS One*. 16(8):e0255999.
- 341 21. Federal Ministry of Health & Nigeria Centre for Disease Control, National Interim
342 Guidelines for Clinical Management of COVID-19. 2020.
343 [https://covid19.ncdc.gov.ng/media/files/National_Interim_Guidelines_for_Clinical_Manage](https://covid19.ncdc.gov.ng/media/files/National_Interim_Guidelines_for_Clinical_Management_of_COVID-19_v3.pdf)
344 [ment_of_COVID-19_v3.pdf](https://covid19.ncdc.gov.ng/media/files/National_Interim_Guidelines_for_Clinical_Management_of_COVID-19_v3.pdf)
- 345 22. Clinical spectrum. In: COVID-19 Treatment Guidelines [Internet]. [cited 7 Mar 2023].
346 <https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/>
- 347 23. Freire-Paspuel B, Garcia-Bereguain MA. 2021. Clinical performance and analytical
348 sensitivity of three SARS-CoV-2 nucleic acid diagnostic tests. *Am J Trop Med Hyg* 104:
349 1516–1518.

- 350 24. Reva ON, Sorokulova IB, Smirnov VV. 2001. Simplified technique for identification of the
351 aerobic spore-forming bacteria by phenotype. *Int J Syst Evol Microbiol* 51: 1361–1371.
- 352 25. Roberts MS, Nakamura LK, Cohan FM. 1994. *Bacillus mojavensis* sp. nov., distinguishable
353 from *Bacillus subtilis* by sexual isolation, divergence in DNA sequence, and differences in
354 fatty acid composition. *Int J Syst Bacteriol* 44: 256–264.
- 355 26. Goto K, Omura T, Hara Y, Sadaie Y. 2000 Application of the partial 16S rDNA sequence as
356 an index for rapid identification of species in the genus *Bacillus*. *J Gen Appl Microbiol* 46:
357 1–8.
- 358 27. National code of health research ethics FEDERAL MINISTRY OF HEALTH. In: Nhrec.net
359 [Internet]. [cited 7 Mar 2023]. Available: [http://nhrec.net/nhrec/wp-](http://nhrec.net/nhrec/wp-content/uploads/2018/10/NCHRE_Aug_07.pdf)
360 [content/uploads/2018/10/NCHRE_Aug_07.pdf](http://nhrec.net/nhrec/wp-content/uploads/2018/10/NCHRE_Aug_07.pdf)
- 361 28. Turnbull PCB. 1996. *Bacillus*. In: Baron S, editor. *Medical Microbiology*. 4th edition.
362 Galveston (TX): University of Texas Medical Branch at Galveston
- 363 29. Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, Bennett. 2014. principles and practice of
364 infectious diseases E-book. 8th ed. Saunders
- 365 30. La Jeon Y, Yang JJ, Kim MJ, Lim G, Cho SY, Park TS, Suh JT, Park YH, Lee MS, Kim SC,
366 Lee HJ. 2021. Combined *Bacillus licheniformis* and *Bacillus subtilis* infection in a patient
367 with oesophageal perforation. *J Med Microbiol* 61(Pt 12):1766-1769.
- 368 31. Michelotti F, Bodansky HJ. 2015. *Bacillus cereus* causing widespread necrotising skin
369 infection in a diabetic person. *Pract Diabetes* 32: 169–170a.
- 370 32. Orrett FA. 2000. Fatal *Bacillus cereus* bacteremia in a patient with diabetes. *J Natl Med*
371 *Assoc* 92:206–208.

- 372 33. Sandrin C, Peypoux F, Michel G. 1990. Coproduction of surfactin and iturin A, lipopeptides
373 with surfactant and antifungal properties, by *Bacillus subtilis*. *Biotechnol Appl Biochem* 12:
374 370–375.
- 375 34. Liu J, Li W, Zhu X, Zhao H, Lu Y, Zhang C, Lu Z. 2019. Surfactin effectively inhibits
376 *Staphylococcus aureus* adhesion and biofilm formation on surfaces. *Appl Microbiol*
377 *Biotechnol* 103(11):4565-4574.
- 378 35. Zhao H, Shao D, Jiang C, Shi J, Li Q, Huang Q, Rajoka MSR, Yang H, Jin M. 2017.
379 Biological activity of lipopeptides from *Bacillus*. *Appl Microbiol Biotechnol* 101(15):5951-
380 5960.
- 381 36. Tao Y, Bie X-M, Lv F-X, Zhao H-Z, Lu Z-X. 2011. Antifungal activity and mechanism of
382 fengycin in the presence and absence of commercial surfactin against *Rhizopus stolonifer*. *J*
383 *Microbiol* 49:146–150.
- 384 37. Musuuza JS, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safdar N. 2021.
385 Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other
386 pathogens: A systematic review and meta-analysis. *PLoS One* 16:e0251170.
- 387 38. Bahceci I, Yildiz IE, Duran OF, Soztanaci US, Kirdi Harbawi Z, Senol FF, Demiral G. 2022.
388 Secondary Bacterial Infection Rates Among Patients With COVID-19. *Cureus* 14(2):e22363.
- 389 39. Lansbury L, Lim B, Baskaran V, Lim WS. 2020. Co-infections in people with COVID-19: a
390 systematic review and meta-analysis. *J Infect* 81: 266–275.
- 391 40. Shafran N, Shafran I, Ben-Zvi H, Sofer S, Sheena L, Krause I, Shlomain A, Goldberg E, Sklan
392 EH. 2021. Secondary bacterial infection in COVID-19 patients is a stronger predictor for
393 death compared to influenza patients. *Sci Rep* 11(1):12703.

394 41. Davies-Bolorunduro OF, Fowora MA, Amoo OS, Adeniji E, Osulale KA, Oladele O,
395 Onuigbo TI, Obi JC, Oraegbu J, Ogundepo O, Ahmed RA, Usman OA, Iyapo BG, Dada AA,
396 Onyia N, Adegbola RA, Audu RA, Salako BL. 2022. Evaluation of respiratory tract bacterial
397 co-infections in SARS-CoV-2 patients with mild or asymptomatic infection in Lagos,
398 Nigeria. Bull Natl Res Cent. 46(1):115.